Our portfolio of patented novel anti-inflammatory peptides have application for the treatment of a variety of inflammatory diseases.  Peptide P13 is the most extensively characterized peptide and is being developed as a treatment for hearing loss seen in patients with otitis media and in individuals exposed to excessive noise.


  • Peptide P13 is an inhibitor of multiple TLRs (TLR2, TLR4, and TLR9) and  multiple pro-inflammatory cytokines and is being developed as a treatment for hearing loss.


  • Peptide P16 is an inhibitor of TLR4 and TLR9 and multiple pro-inflammatory cytokines and is being developed for treatment of atherosclerosiss and inflammatory bowel disease and other autoimmune diseases.


  • Peptide P7 is an inhibitor of TLR3 and TLR4 and multiple pro-inflammatory cytokines and is being developed for the treatment of pulmonary inflammation.

13therapeutics, Inc.